Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced ...
Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free ...
Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...
A research team led by Prof. Ben Ko Chi-bun, Associate Professor of the PolyU Department of Applied Biology and Chemical Technology, has discovered the critical mechanism of action of tetrandrine, a ...
Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
A research team at the Seville Biomedical Institute (IBis) has identified a new molecular mechanism that explains the high sensitivity of Ewing sarcoma (an aggressive bone cancer that mainly affects ...
The integration of artificial intelligence (AI) into drug discovery is revolutionizing pharmaceutical research by providing sophisticated tools for understanding and predicting complex biological ...
A research team at the Seville Biomedical Institute (IBis) has identified a new molecular mechanism that explains the high sensitivity of Ewing sarcoma (an aggressive bone cancer that mainly affects ...
Functional vision improvements are reported, with optimal pupil size considerations for varying light conditions being ...
Sequels are opportunities to either build upon a predecessor and push boundaries, or refine what was already great and deliver that again with a stronger focus. With Ghost of Yotei, developer Sucker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback